DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLIC... by Foroni, C, Fox, S, Berruti, A, Dogliotti, L, Bottini, A, Harris, A, Generali, D

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. by Milani, M, Rzymski, T, Mellor, H, Pike, L, Bottini, A, Generali, D, Harris, A

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Bonardi, S, Dogliotti, L, Harris, A, Bottini, A

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients. by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration by Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, Bottini A, Chin Yee D, Mukkamala K

Get full text

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. by Generali, D, Berruti, A, Foroni, C, Bazzola, L, Andreis, D, Allevi, G, Bersiga, A, Dogliotti, L, Fox, S, Harris, A, Bottini, A

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer. by Fox, S, Generali, D, Berruti, A, Bates, G, Banham, A, Bonardi, S, Milani, M, Dionisio, R, Brizzi, M, Dogliotti, L, Bottini, A, Harris, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. by Generali, D, Buffa, F, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Papotti, M, Dogliotti, L, Bottini, A, Harris, A, Fox, S

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. by Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. by Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. by Generali, D, Fox, S, Brizzi, M, Allevi, G, Bonardi, S, Aguggini, S, Milani, M, Bersiga, A, Campo, L, Dionisio, R, Vergoni, F, Giardini, R, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Synergistic activity of letrozole and sorafenib on breast cancer cells. by Bonelli, M, Fumarola, C, Alfieri, R, La Monica, S, Cavazzoni, A, Galetti, M, Gatti, R, Belletti, S, Harris, A, Fox, S, Evans, D, Dowsett, M, Martin, L, Bottini, A, Generali, D, Petronini, P

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones by Cavazzoni, A, Bonelli, M, Fumarola, C, La Monica, S, Airoud, K, Bertoni, R, Alfieri, R, Galetti, M, Tramonti, S, Galvani, E, Harris, A, Martin, L, Andreis, D, Bottini, A, Generali, D, Petronini, P